---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Efficacy and safety"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Efficacy and safety. Topics: Summary: ONWARD1 and ONWARD2 phase 3 trials, Summary: ONWARD3 long-term extension, Summary: STRIDE phase 2 trial and its open-label extension, and Summary: phase 1 studies. 4 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary/efficacy-and-safety"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Efficacy and safety

<a id="heading-1.1.2"></a>

## 1.1.2 Envudeucitinib Efficacy and Safety

<a id="topic-1.1.2-1"></a>

### Summary: ONWARD1 and ONWARD2 phase 3 trials

ONWARD1 and ONWARD2 are two parallel global, multicenter, randomized, double-blind, placebo- and active-comparator-controlled 24-week trials in adults with moderate-to-severe plaque psoriasis. Participants were randomized 2:1:1 to envudeucitinib 40 mg twice daily, placebo, or apremilast, and placebo participants rolled over to envudeucitinib at week 16. The co-primary endpoints were PASI 75 and sPGA 0/1 against placebo at week 16. Enrollment is reported as 912 (ONWARD1) and 862 (ONWARD2) participants in the ClinicalTrials.gov records, as arm sizes of 459, 230, and 223 (ONWARD1) and 433, 211, and 215 (ONWARD2) in the congress presentation, and as “N=1771” for both trials in a company press release. The ONWARD1 and ONWARD2 results come from company press releases, a company webcast presentation, and congress presentations and posters by Blauvelt et al. and Hawkes et al.; both ClinicalTrials.gov records read “No Results Posted”.

The topline press release states that envudeucitinib was superior to placebo on both co-primary endpoints in each trial (p < 0.0001). At week 16, PASI 75 was achieved by 76.5% of envudeucitinib, 18.7% of placebo, and 44.4% of apremilast participants in ONWARD1, and by 70.4%, 13.7%, and 38.6% in ONWARD2. sPGA 0/1 is quoted only as an average across both trials: 59% in the topline press release and approximately 60% at week 16 in the congress presentation.

Against apremilast, PASI 90 at week 16 was 59.9% vs 21.5% in ONWARD1 and 53.1% vs 20.9% in ONWARD2, and PASI 100 was 29.4% vs 4.0% and 27.7% vs 7.9% (placebo: PASI 90 4.8% and 4.3%, PASI 100 0.9% in each trial). At week 24, PASI 90 was 68.0% vs 25.6% in ONWARD1 and 62.1% vs 25.6% in ONWARD2, and PASI 100 was 41.0% vs 8.5% and 39.5% vs 13.0%. The topline press release states that envudeucitinib was superior to apremilast in each trial (p<0.0001) on all PASI endpoints at week 24.

Itch and quality-of-life results are reported for both trials together. The congress presentation reports a mean decrease of more than 4 points from baseline in worst pruritus NRS by week 12, and a press release reports an average improvement of more than 4 points by week 16. Approximately one-third of envudeucitinib participants had an improvement of at least 4 points at week 2. At week 16, complete itch resolution (NRS 0) is reported as “over one-third” in the itch poster and about 40% in a press release, and minimal itch (NRS 0/1) as more than half and approximately 60%, respectively. A press release reports that approximately 50% achieved DLQI 0/1 by week 12; the DLQI 0/1 endpoint was assessed in participants with baseline DLQI of at least 2.

In the pooled safety population through week 16, at least one TEAE occurred in 524 of 890 envudeucitinib participants (58.9%), 166 of 441 placebo participants (37.6%), and 223 of 438 apremilast participants (50.9%); SAEs occurred in 19 (2.1%), 5 (1.1%), and 5 (1.1%), and TEAEs leading to discontinuation in 30 (3.4%), 7 (1.6%), and 9 (2.1%). Through week 16, rates of headache were 10.3%, 2.5%, and 9.1%, nasopharyngitis 7.2%, 4.8%, and 3.7%, acne 6.0%, 0.7%, and 0.7%, diarrhea 1.6%, 2.5%, and 8.2%, and nausea 2.2%, 0.9%, and 5.3%. Through week 24, the overall envudeucitinib group (n = 1280) had TEAEs in 693 participants (54.1%), SAEs in 25 (2.0%), and TEAEs leading to discontinuation in 35 (2.7%), compared with 248 (56.6%), 6 (1.4%), and 12 (2.7%) in the apremilast group (n = 438). The congress presentation reports serious infections in 0.7% and malignancies in 0.2% of envudeucitinib participants at week 24, no deaths, no MACE or cytopenia signals, and no tuberculosis reactivation; thirty-nine participants with latent or treated tuberculosis were enrolled.

Source: [ClinicalTrials.gov NCT06586112](https://clinicaltrials.gov/study/NCT06586112); [ClinicalTrials.gov NCT06588738](https://clinicaltrials.gov/study/NCT06588738); [Alumis press release, Fall Clinical 2026 ONWARD data (2026)](https://investors.alumis.com/news-releases/news-release-details/alumis-announces-new-phase-3-data-demonstrating-envudeucitinib); [Alumis presentation, ONWARD1 and ONWARD2 topline webcast (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-2.htm); [Alumis press release, ONWARD1 and ONWARD2 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926001073/tm262035d1_ex99-1.htm); [Alumis press release, AAD 2026 ONWARD data (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926036386/tm269978d1_ex99-1.htm); [Blauvelt et al. (2026c)](https://www.alumis.com/file.cfm/613/docs/blauvelt_aad%202026_onward_oral_presentation.pdf); [Blauvelt et al. (2026d)](https://www.alumis.com/file.cfm/613/docs/esk2507192m_eadv-2026-onward-topline-encore-poster_14sep2026-2.pdf); [Hawkes et al. (2026)](https://www.alumis.com/file.cfm/613/docs/envudeucitinib-itch-relief-fall-clinical.pdf)

<a id="topic-1.1.2-2"></a>

### Summary: ONWARD3 long-term extension

ONWARD3 is an ongoing phase 3 long-term extension that participants completing week 24 of ONWARD1 or ONWARD2 were eligible to enter. All entrants received open-label envudeucitinib for 24 weeks regardless of parent-study treatment; the first 200 participants achieving PASI 75 at week 24 of ONWARD3 could enter a 24-week randomized withdrawal period, and the trial is designed to provide up to 96 weeks of data. Enrollment is given as 1680 (estimated, ClinicalTrials.gov), 1,509 entrants (press release), and 773, 367, and 369 entrants from the envudeucitinib, placebo, and apremilast arms of the parent trials (congress poster).

In a non-responder imputation analysis of the 773 participants from the envudeucitinib arms, with up to 48 weeks of continuous treatment, 75% achieved PASI 90 and 54% achieved PASI 100 (press release); the poster reports PASI 75 in 85.2%, sPGA 0/1 in 75.2%, and sPGA 0 in 54.5% of those continuously treated at week 48. A separate integrated non-responder imputation analysis of the 890 participants originally randomized to envudeucitinib, including those who did not enter ONWARD3, reports PASI 90 in 66% and PASI 100 in 47% after 48 weeks. Among participants with a response at the end of the parent trials, the response was maintained after 24 weeks in ONWARD3 by 89.8% for PASI 75 (n = 678), 89.4% for PASI 90 (n = 575), 80.1% for PASI 100 (n = 357), 86.2% for an improvement of at least 4 points in worst pruritus NRS (n = 509), and 86.3% for DLQI 0/1 (n = 497).

Through week 48, at least one TEAE occurred in 521 (67.4%), 253 (68.9%), and 268 (72.6%) participants from the envudeucitinib, placebo, and apremilast parent arms, SAEs in 25 (3.2%), 16 (4.4%), and 9 (2.4%), and TEAEs leading to discontinuation in 23 (3.0%), 11 (3.0%), and 25 (6.8%). The poster reports no deaths, MACE events, lymphomas, or tuberculosis reactivation, and three positive tuberculosis tests without clinical signs or symptoms. Results of the randomized withdrawal period have not been reported.

Source: [ClinicalTrials.gov NCT06846541](https://clinicaltrials.gov/study/NCT06846541); [Alumis press release, ONWARD3 topline results (2026)](https://www.sec.gov/Archives/edgar/data/1847367/000110465926093353/tm2622655d1_ex99-1.htm); [Lebwohl et al. (2026b)](https://www.alumis.com/file.cfm/613/docs/onward3-fall-clinical.pdf)

<a id="topic-1.1.2-3"></a>

### Summary: STRIDE phase 2 trial and its open-label extension

STRIDE was a phase 2, randomized, double-blinded, placebo-controlled, 16-week study (12 weeks of treatment and 4 weeks of safety follow-up) in which 228 participants were randomized and 227 dosed with placebo or envudeucitinib 10 mg QD, 20 mg QD, 40 mg QD, 20 mg BID, or 40 mg BID. At week 12 (modified intent-to-treat set, nonresponder imputation), the primary endpoint of PASI 75 was achieved by 0 of 38 placebo participants (0%) and by 19%, 33%, 56%, 56%, and 64% in the 10 mg QD, 20 mg QD, 20 mg BID, 40 mg QD, and 40 mg BID arms (P < .0001 for 40 mg BID). With 40 mg BID, 39% achieved PASI 90, 15% PASI 100, 59% sPGA 0/1 (placebo 8%), and 64% DLQI 0/1 (placebo 18%), and the average pruritus NRS improved by 5 points (placebo 1 point). In the safety analysis set of the 16-week study, TEAEs occurred in 25 of 39 participants (64.1%) receiving 40 mg BID, 95 of 189 (50.3%) receiving any envudeucitinib dose, and 15 of 38 (39.5%) receiving placebo; SAEs occurred in 5 envudeucitinib participants (2.6%) and in none receiving 40 mg BID or placebo, and 5 participants (2.6%) discontinued envudeucitinib due to an AE. There were no deaths and no cases of tuberculosis, herpes zoster, opportunistic infections, or oral ulcers. An exposure-response analysis supported selection of 40 mg BID for the phase 3 trials.

In the open-label extension, 165 participants who completed STRIDE were enrolled at North American sites and assigned to 40 mg QD or 40 mg BID; a protocol amendment on 2 January 2024 moved all participants to 40 mg BID between weeks 40 and 64. At week 52 with 40 mg BID, the article text reports PASI 75 in 78%, PASI 90 in 61%, PASI 100 in 39%, sPGA 0 in 39%, and DLQI 0/1 in 61% of participants; the efficacy table gives PASI 100 as 31 of 80 (38.8%) in the original 40 mg BID group and 47 of 144 (32.6%) in the overall 40 mg BID group. Through week 52 (safety analysis population, N = 164), at least one TEAE occurred in 108 participants (65.9%), at least one SAE in 6 (3.7%), and a TEAE leading to study drug discontinuation in 6 (3.7%). Four SAEs were considered related to study drug (peritonsillar abscess, non-small cell lung cancer, renal cell carcinoma, and arthritis); 2 cases of herpes zoster occurred, and there were no deaths and no cases of tuberculosis.

Source: [Blauvelt et al. (2026a)](https://www.jaad.org/article/S0190-9622%2825%2902466-1/fulltext); [Ucpinar et al. (2024b)](https://www.alumis.com/file.cfm/18/docs/eadv2024_pstr_poppk-er_final.pdf); [Papp et al. (2026)](https://www.jaad.org/article/S0190-9622%2825%2902952-4/fulltext)

<a id="topic-1.1.2-4"></a>

### Summary: phase 1 studies

In the first-in-human study (ACTRN12621000011886), 91 participants were enrolled, 53 in the single ascending dose part and 38 in the multiple ascending dose part, and received a liquid formulation; single doses of 5, 10, 17.5, 25, 50, and 100 mg were given (planned range 5 to 150 mg). The ANZCTR record gives a final sample size of 87. After single doses, median Tmax was 0.8 to 1.1 h and mean terminal half-life 7.5 to 9.3 h. With the liquid formulation at 25 mg, a high-calorie meal reduced Cmax by approximately 50% and delayed median Tmax from 0.75 h to 4 h, with similar AUC0–inf. In the single ascending dose part, TEAEs occurred in 32 participants receiving envudeucitinib (78.0%) and 5 receiving placebo (41.6%), there were no serious TEAEs, and headache was the most common TEAE.

In the 14-day multiple-dose study of the immediate release tablet (ESK-001-003), 49 participants were enrolled (36 envudeucitinib, 13 placebo). The mean half-life after the last dose on Day 14 ranged from 7.6 to 12.4 h, steady state was achieved by Day 3, dosing every 12 hours produced approximately 2-fold accumulation, and trough concentrations at 40 mg Q12 remained above the in vitro human whole blood 90% pSTAT inhibitory concentration. TEAEs occurred in 27 envudeucitinib (75.0%) and 11 placebo (84.6%) participants. Across the first-in-human and multiple-dose studies, no deaths, serious TEAEs, or severe TEAEs were reported, and a concentration-QTc analysis excluded a placebo-corrected QTcF effect exceeding 10 ms at plasma concentrations up to approximately 1000 ng/mL.

In the pharmacokinetic study in Japanese, Chinese, and Caucasian healthy participants (24 participants in cohorts of 8), the steady-state half-life on Day 7 of 40 mg BID was 7.6, 8.4, and 9.1 h; the poster reports similar pharmacokinetic and safety profiles across ethnicities, no serious TEAEs or deaths, and 1 discontinuation (Caucasian cohort, 40 mg BID) for a moderate headache. The QT study ESK-001-019 (52 participants), the hepatic impairment study ESK-001-022 (32), the renal impairment study ESK-001-023 (16), and the tablet and liquid relative bioavailability study ESK-001-002 (14) are completed, and their ClinicalTrials.gov records read “No Results Posted”.

Source: [Ucpinar et al. (2024c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11602527/); [ANZCTR ACTRN12621000011886](https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=380885); [ClinicalTrials.gov NCT05431634](https://clinicaltrials.gov/study/NCT05431634); [Noh et al. (2025)](https://www.alumis.com/file.cfm/18/docs/aad2025_pstr_ethnobridging_final.pdf); [ClinicalTrials.gov NCT07378579](https://clinicaltrials.gov/study/NCT07378579); [ClinicalTrials.gov NCT06952634](https://clinicaltrials.gov/study/NCT06952634); [ClinicalTrials.gov NCT06962774](https://clinicaltrials.gov/study/NCT06962774); [ClinicalTrials.gov NCT05330858](https://clinicaltrials.gov/study/NCT05330858)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
